The decision whom to biopsy can be supported by risk calculators (RCs) incorporating demographic and clinical information such as age, digital rectal exam (DRE), prostate-specific antigen (PSA), and prostate volume, e.g., RCs from the European Randomized Study of Screening for Prostate Cancer (ERSPC) combine this information in logistic regression models [11] and visualize it using nomograms [12]. This evidence concerns the gene KLK3 and Familial prostate cancer.